| __timestamp | Alnylam Pharmaceuticals, Inc. | Jazz Pharmaceuticals plc |
|---|---|---|
| Wednesday, January 1, 2014 | 50561000 | 1172875000 |
| Thursday, January 1, 2015 | 41097000 | 1324803000 |
| Friday, January 1, 2016 | 47159000 | 1487973000 |
| Sunday, January 1, 2017 | 89912000 | 1618693000 |
| Monday, January 1, 2018 | 74908000 | 1890922000 |
| Tuesday, January 1, 2019 | 219750000 | 2161761000 |
| Wednesday, January 1, 2020 | 492853000 | 2363567000 |
| Friday, January 1, 2021 | 844287000 | 3094238000 |
| Saturday, January 1, 2022 | 1037418000 | 3659374000 |
| Sunday, January 1, 2023 | 1828292000 | 3834204000 |
| Monday, January 1, 2024 | 2248243000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, Alnylam Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc have showcased remarkable revenue trajectories over the past decade. Since 2014, Alnylam has transformed its revenue from a modest $50 million to an impressive $1.8 billion by 2023, marking a staggering growth of over 3,500%. Meanwhile, Jazz Pharmaceuticals has consistently maintained its lead, growing from $1.2 billion in 2014 to nearly $3.8 billion in 2023, a robust increase of over 200%.
This revenue showdown highlights the dynamic nature of the pharmaceutical industry, where innovation and strategic market positioning are key. Alnylam's rapid ascent underscores its successful product pipeline and market expansion, while Jazz's steady growth reflects its stronghold in niche markets. As both companies continue to innovate, the coming years promise even more exciting developments in their financial journeys.
Eli Lilly and Company and Jazz Pharmaceuticals plc: A Comprehensive Revenue Analysis
Revenue Showdown: Bristol-Myers Squibb Company vs Alnylam Pharmaceuticals, Inc.
Revenue Insights: Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc. Performance Compared
Alnylam Pharmaceuticals, Inc. vs Exelixis, Inc.: Examining Key Revenue Metrics
Alnylam Pharmaceuticals, Inc. vs Halozyme Therapeutics, Inc.: Examining Key Revenue Metrics
Breaking Down Revenue Trends: Alnylam Pharmaceuticals, Inc. vs ImmunityBio, Inc.
Alnylam Pharmaceuticals, Inc. and Mesoblast Limited: A Comprehensive Revenue Analysis
Revenue Insights: Biogen Inc. and Jazz Pharmaceuticals plc Performance Compared
Bio-Techne Corporation vs Jazz Pharmaceuticals plc: Examining Key Revenue Metrics
Annual Revenue Comparison: Jazz Pharmaceuticals plc vs Halozyme Therapeutics, Inc.
Jazz Pharmaceuticals plc or Veracyte, Inc.: Who Leads in Yearly Revenue?
Jazz Pharmaceuticals plc vs Amphastar Pharmaceuticals, Inc.: Annual Revenue Growth Compared